The Epstein-Barr virus (EBV) is closely associated with human malignancies which develop in both lymphoid and epithelial cells. The goal of this research program is to determine the role of EBV in the genesis of malignancy and to characterize the viral genes which contribute to oncogenesis. Work from our laboratory has analyzed EBV expression in epithelial and lymphoid malignancies. The EBV nuclear antigen, EBNA 1, the membrane proteins, LMP 1 and LMP 2, and a previously undescribed gene from the BamHI A rightward open reading frame O (BARF O) are consistently transcribed in nasopharyngeal carcinoma (NPC) and parotid carcinoma whereas in some lymphomas, LMP1 and LMP2, EBNAs 1-6, an BARFO may be transcribed. In Burkitt's Lymphomas only EBNA1 is thought to be expressed. It is likely that EBV alters cellular growth in a complex manner which may involve interaction of several cellular types and synthesis of growth factors and interleukins. This type of cellular interaction cannot be duplicated in assays in vitro. Transgenic mice provide an opportunity to asses the effects of individual viral genes in the context of the entire organism. In addition, some of the viral genes may function in a cell-type specific manner. The ability to target expression in transgenic mice to specific tissues provides the opportunity to assess the cell-specific effects of expression of the viral genes. The guiding hypothesis is that EBV genes directly alter cell growth and contribute to oncogenesis. To express the EBV transforming gene, LMP1, and the associated integral membrane protein, lMP2, in the appropriate cell types, transgenic mice lineages have been established containing the lMP1 and LMP2 genes under the control of the immunoglobulin promoter/enhancer (IG). The expression of the genes will be assessed through analysis of RNA and protein. Mice transgenic for both lMP1 and lMP2 will be produced by cross-breeding. The growth properties of the B lymphocytes will be assessed in vitro and in SCID mice. To develop a model of latent transforming EBV infection in epithelial cells, the k14 keratin promoter will be used to target expression to the basal epithelium. Transgenic lineages expressing lMP1 and LMP2 under the control of the k14 promoter will be developed and analyzed for expression of the viral genes, altered growth properties, and histopathology. Finally, to identify activation pathways which complement LMP1 and LMP2 expression, EBV transgenic mice will be bred to mice expressing specific cellular oncogenes in lymphoid and epithelial cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA019014-20
Application #
6236414
Study Section
Project Start
1997-05-01
Project End
1998-04-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
20
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
DeKroon, Robert M; Gunawardena, Harsha P; Edwards, Rachel et al. (2018) Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. MBio 9:
Nicholls, Thomas J; Nadalutti, Cristina A; Motori, Elisa et al. (2018) Topoisomerase 3? Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell 69:9-23.e6
El-Mallawany, Nader Kim; Kamiyango, William; Villiera, Jimmy et al. (2018) Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol :1-7
Selitsky, Sara R; Marron, David; Mose, Lisle E et al. (2018) Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. mSystems 3:
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Lyons, Danielle E; Yu, Kuan-Ping; Vander Heiden, Jason A et al. (2018) Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication. J Virol 92:
Bigi, Rachele; Landis, Justin T; An, Hyowon et al. (2018) Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 115:E11379-E11387
El-Mallawany, Nader Kim; Villiera, Jimmy; Kamiyango, William et al. (2018) Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer 13:33
Kobayashi, E; Aga, M; Kondo, S et al. (2018) C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes. mSphere 3:
Hopcraft, Sharon E; Pattenden, Samantha G; James, Lindsey I et al. (2018) Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 14:e1007267

Showing the most recent 10 out of 324 publications